Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | GHSR | Q92847 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081571 | 1.00 | KCNH2 (0.40) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL5075657 | 1.00 | KCNH2 (0.40) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL6493039 | 0.93 | LMNA (0.39) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL6493042 | 0.93 | LMNA (0.39) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL5077602 | 0.93 | KDM4E (0.40) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL5077604 | 0.93 | KDM4E (0.40) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL5077620 | 0.93 | KDM4E (0.40) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL5078270 | 0.92 | ALDH1A1 (0.41) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL5078273 | 0.92 | ALDH1A1 (0.41) | KCNH2ADORA3CNR1HRH1OPRK1 | |
| SCHEMBL5078275 | 0.92 | ALDH1A1 (0.41) | KCNH2ADORA3CNR1HRH1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | claimed |
| US-20050107356-A1 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2005-05-19 | — | — | US | claimed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | claimed |
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | claimed |
| EP-1328269-B1 | ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN FOR TREATING OBESITY | AVENTIS PHARMA SA (FR) | 2004-05-26 | — | — | EP | claimed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | claimed |
| EP-1328269-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND A SIBUTRAMIN FOR TREATING OBESITY | Aventis Pharma S.A. (FR) | 2003-07-23 | — | — | EP | claimed |
| EP-1112251-B1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-07 | — | — | EP | claimed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | claimed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | claimed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | claimed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | claimed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | claimed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | claimed |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-7148258-B2 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | KCNH2 463/4885ADORA3 168/4885CNR1 1115/4885 |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | KCNH2 1992/4885ADORA3 153/4885CNR1 2/4885 |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AZI2, QDPR, ADRA2A | KCNH2 569/4885ADORA3 157/4885CNR1 1442/4885 |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | CNR2, CNR1, GPR119 | KCNH2 1992/4885ADORA3 153/4885CNR1 2/4885 |
| US-20050107356-A1 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | CNR1, CNR2, GPR18 | KCNH2 1568/4885ADORA3 149/4885CNR1 1/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | KCNH2 542/4885ADORA3 141/4885CNR1 515/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | KCNH2 789/4885ADORA3 152/4885CNR1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.